huahaipharm(SH:600521) Xin Lang Cai Jing·2026-01-14 07:25Group 1 - The core point of the news is that Huahai Pharmaceutical's stock has experienced a decline, with a 5.65% drop over the last three days, closing at 17.55 yuan per share on January 14, with a total market capitalization of 26.277 billion yuan [1] - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The company's revenue composition includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - From the perspective of major fund holdings, one fund under Qianhai United Fund holds Huahai Pharmaceutical as its eighth largest position, with 40,000 shares representing 3.38% of the fund's net value [2] - The fund, Qianhai United National Health Mixed A (003581), has incurred a floating loss of approximately 5,600 yuan today and a total floating loss of 42,000 yuan during the three-day decline [2] - The fund was established on December 29, 2016, with a latest scale of 15.6476 million yuan, and has achieved a year-to-date return of 9.78% [2]